Datapoint: FDA Expands HAE Nod for Takeda’s Takhzyro
Takeda’s Takhzyro last week won expanded use as a prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients age 2 to 12. The injectable was previously approved in patients 12 and older. For that indication, Takhzyro holds covered or better status for 95% of all insured lives under the medical benefit. It is covered for just 15% of insured lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 2/6/23